Ruxolitinib; Tofacitinib/Strong CYP3A4 Inhibitors
Serious. These medicines may interact and cause very harmful effects. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
Some medicines may slow down how quickly your body processes ruxolitinib or tofacitinib.
What might happen:
The amount of ruxolitinib or tofacitinib in your blood may increase and cause more or more severe side effects than expected.
What you should do about this interaction:
Make sure your healthcare professionals (e.g. doctor or pharmacist) know that you are taking these medicines together. Your doctor may want to adjust the dose of your ruxolitinib or tofacitinib while you are taking your other medicine. Let your doctor know right away if you develop any unusual bleeding, bruising, fatigue, shortness of breath, chills, aches, fever, nausea, vomiting, weakness, or a painful rash/blisters.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
1.Jakafi (ruxolitinib) US prescribing information. Incyte Corporation November, 2013.
2.Xeljanz (tofacitinib) US prescribing information. Pfizer Inc. November, 2012.